|
72
|
| 227 |
SEMA3A
|
|
decreases_phosphorylation of
|
AKT1
|
|
|
16495486
|
Amyotrophic lateral sclerosis
|
|
103
|
| 107506 |
AKT1-phosSer473Thr308
|
|
increases_activity of
|
AKT1
|
AKT1-phosSer473Thr308 = active AKT1;
|
|
8978681
|
Alzheimer disease
|
|
113
|
| 385 |
Insulin
|
|
increases_activity of
|
AKT1
|
in L6 myotubes; by phosphorylation
|
| 395 |
Insulin
|
|
increases_phosphorylation of
|
AKT1
|
at Thr308 and Ser473
|
| 396 |
Wortmannin
|
|
decreases_phosphorylation of
|
AKT1
|
at Thr308 and Ser473
|
|
8978681
|
Alzheimer disease
|
|
115
|
| 388 |
Schizophrenia
|
|
decreases_expression of
|
AKT1
|
in prefrontal cortex; in Irish population
|
|
17825267
|
Schizophrenia
|
|
116
|
| 389 |
Insulin
|
|
increases_activity of
|
AKT1
|
|
| 391 |
IGF1
|
|
increases_activity of
|
AKT1
|
|
| 393 |
Insulin
|
|
increases_phosphorylation of
|
AKT1
|
at Thr308 and Ser473
|
| 394 |
IGF1
|
|
affects_phosphorylation of
|
AKT1
|
at Thr308 and Ser473
|
| 397 |
Wortmannin
|
|
decreases_phosphorylation of
|
AKT1
|
at Thr308 and Ser473
|
| 401 |
MAPKAPK2
|
|
increases_phosphorylation of
|
AKT1
|
at Ser473
|
| 404 |
MAPKAPK2
|
|
increases_activity of
|
AKT1
|
by phosphorylation at Ser473
|
|
8978681
|
Alzheimer disease
|
|
122
|
| 909 |
PSEN1
|
|
affects_activity of
|
AKT1
|
|
|
11527574
|
Alzheimer disease
|
|
275
|
| 1117 |
ANG
|
|
increases_activity of
|
AKT1
|
|
|
19109488
|
Amyotrophic lateral sclerosis
|
|
278
|
| 1129 |
ANG
|
|
increases_activity of
|
AKT1
|
|
| 1131 |
ANG-p.K40I
|
NOT |
increases_activity of
|
AKT1
|
|
|
19109488
|
Amyotrophic lateral sclerosis
|
|
368
|
| 1511 |
ob/ob mouse
|
|
affects_activity of
|
AKT1
|
|
|
19363290
|
Diabetes mellitus, type II
Obesity
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
397
|
| 1705 |
NIR KO mouse
|
|
decreases_phosphorylation of
|
AKT1
|
in brain
|
|
14981233
|
Alzheimer disease
|
|
418
|
| 1890 |
AKT1
|
|
interacts (colocalizes) with
|
PDPK1
|
|
| 1943 |
AKT1
|
|
is localized in
|
brain
|
|
| 1954 |
Amyloid beta peptide
|
|
decreases_activity of
|
AKT1
|
|
| 1955 |
Amyloid beta peptide
|
|
interacts (colocalizes) with
|
AKT1
|
|
| 1976 |
PDPK1
|
|
increases_phosphorylation of
|
AKT1
|
at Thr308; phosphorylation at Ser473 is required for full Akt activity;
|
|
19144826
|
Alzheimer disease
|
|
427
|
| 1867 |
Amyloid beta peptide
|
|
decreases_phosphorylation of
|
AKT1
|
if AKT is insulin-induced;
|
| 1868 |
Amyloid beta peptide
|
|
decreases_activity of
|
AKT1
|
if AKT is insulin-induced;
|
| 1883 |
AKT1
|
|
interacts (colocalizes) with
|
PDPK1
|
via intraneuronal beta-amyloid
|
| 2001 |
Amyloid beta peptide (42)
|
|
decreases_activity of
|
AKT1
|
concerning activity of Akt1 on the GSK substrate
|
| 2004 |
AKT1
|
|
is_part_of
|
AKT1-PDPK1 interaction
|
|
| 129312 |
Insulin
|
|
increases_phosphorylation of
|
AKT1
|
in cell culture
|
| 134780 |
AKT1-phos
|
|
increases_activity of
|
AKT1
|
in cell culture; inhibited by intraneuronal beta-amyloid expression
|
|
19144826
|
Alzheimer disease
|
|
488
|
| 2302 |
Pioglitazone
|
|
affects_phosphorylation of
|
AKT1
|
in muscle
|
|
12446579
|
Diabetes mellitus, type II
Insulin resistance
|
|
598
|
| 3242 |
high-phytoestrogen soy-based diet
|
|
affects_phosphorylation of
|
AKT1
|
at Thr308/Ser473 of AKT1
|
|
18420492
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
622
|
| 3293 |
VEGFA
|
|
increases_activity of
|
AKT1
|
in spinal cord; in serum-deprived cultures
|
| 3300 |
VEGFA
|
|
increases_phosphorylation of
|
AKT1
|
in spinal cord; in serum-deprived cultures
|
|
19041930
|
Amyotrophic lateral sclerosis
|
|
627
|
| 3330 |
VEGFA
|
|
increases_activity of
|
AKT1
|
in spinal cord motoneurons
|
| 3331 |
VEGFA
|
|
increases_phosphorylation of
|
AKT1
|
in spinal cord motoneurons
|
|
18182045
|
Amyotrophic lateral sclerosis
|
|
654
|
| 3511 |
DGAT1
|
|
affects_activity of
|
AKT1
|
in skeletal muscle; if stimulated by insulin
|
|
15569818
|
Diabetes mellitus, type II
Obesity
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
655
|
| 3497 |
(5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline)
|
|
increases_activity of
|
AKT1
|
|
| 3498 |
(5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline)
|
|
increases_phosphorylation of
|
AKT1
|
at Ser-473
|
| 3499 |
(5-[4-propargylpiperazin-1-ylmethyl]-8-hydroxyquinoline)
|
|
increases_activity of
|
AKT1
|
|
| 3500 |
(5-[4-propargylpiperazin-1-ylmethyl]-8-hydroxyquinoline)
|
|
increases_phosphorylation of
|
AKT1
|
at Ser-473
|
|
19638399
|
Amyotrophic lateral sclerosis
|
|
737
|
| 4157 |
6-OHDA
|
|
decreases_phosphorylation of
|
AKT1
|
|
|
18665912
|
Parkinson disease
|
|
792
|
| 4693 |
Alzheimer disease
|
|
increases_quantity of
|
AKT1
|
|
| 4695 |
AKT1
|
|
affects_expression of
|
STUB1
|
|
| 4696 |
AKT1
|
|
increases_activity of
|
MARK2
|
|
| 4697 |
AKT1
|
|
affects_phosphorylation of
|
MAPT
|
|
|
19449461
|
Alzheimer disease
|
|
824
|
| 4800 |
AKT1
|
|
increases_phosphorylation of
|
PPARGC1A
|
in liver
|
| 4802 |
AKT1
|
|
decreases_quantity of
|
PPARGC1A
|
in liver; via increased degradation of PPARGC1A
|
| 4860 |
Insulin
|
|
increases_activity of
|
AKT1
|
in liver
|
| 4861 |
AKT1
|
|
increases_phosphorylation of
|
CRTC2
|
in liver
|
| 4862 |
AKT1
|
|
increases_phosphorylation of
|
PPARGC1A
|
in liver
|
| 4863 |
AKT1
|
|
decreases_quantity of
|
CRTC2
|
in liver; via increased degradation of CRTC2
|
| 4864 |
AKT1
|
|
decreases_quantity of
|
PPARGC1A
|
in liver; via increased degradation of PPARGC1A
|
| 4866 |
AKT1
|
|
decreases_activity of
|
CRTC2
|
in liver
|
| 4867 |
AKT1
|
|
decreases_activity of
|
PPARGC1A
|
in liver
|
|
19770177
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
851
|
| 5063 |
response to oxidative stress
|
|
increases_phosphorylation of
|
AKT1
|
in the presence of DJ-1
|
| 5065 |
PARK7
|
|
increases_phosphorylation of
|
AKT1
|
during oxidative stress
|
| 5073 |
AKT1
|
|
decreases_activity of
|
neuron death
|
in response to H2O2 and in the presence of DJ-1
|
| 5077 |
PARK7
|
|
increases_activity of
|
AKT1
|
|
| 5081 |
AKT1
|
|
is localized in
|
plasma membrane
|
in response to H2O2 and in the presence of DJ-1
|
| 9725 |
AKT1
|
|
affects_activity of
|
protein kinase B signaling
|
|
|
20133695
|
Parkinson disease
|
|
852
|
| 5071 |
PARK7
|
|
increases_phosphorylation of
|
AKT1
|
in response to H2O2
|
| 5072 |
PARK7-p.L166P
|
NOT |
increases_phosphorylation of
|
AKT1
|
in response to H2O2
|
|
20133695
|
Parkinson disease
|
|
855
|
| 6308 |
PARK7
|
|
increases_phosphorylation of
|
AKT1
|
|
|
15766664
|
Breast cancer
Parkinson disease
|
|
861
|
| 5106 |
AKT1
|
|
increases_phosphorylation of
|
GSK3B
|
at Ser9, thereby inactivating GSK3B;
|
| 5108 |
Alzheimer disease
|
|
increases_quantity of
|
AKT1
|
|
| 5117 |
AKT1
|
|
affects_phosphorylation of
|
GSK3
|
at Ser9; this phosphorylated GSK3 is inactivated
|
| 5119 |
AKT1
|
|
increases_quantity of
|
MAPT-hyperphos
|
|
| 19094 |
AKT1
|
|
affects_activity of
|
protein kinase B signaling
|
|
|
12624792
|
Alzheimer disease
|
|
869
|
| 5147 |
Parkinson disease
|
|
decreases_quantity of
|
AKT1
|
in midbrain
|
| 5150 |
Parkinson disease
|
|
decreases_phosphorylation of
|
AKT1
|
in midbrain
|
|
19800394
|
Parkinson disease
|
|
871
|
| 5153 |
AKT1
|
|
decreases_activity of
|
neuron death
|
in PD mice
|
|
17116866
|
Parkinson disease
|
|
885
|
| 5213 |
EGF
|
|
increases_phosphorylation of
|
AKT1
|
|
| 5224 |
PRKN
|
NOT |
increases_phosphorylation of
|
AKT1
|
in synaptosomes
|
|
16862145
|
Parkinson disease
|
|
921
|
| 5568 |
KDR
|
|
increases_activity of
|
AKT1
|
|
|
18178312
|
Amyotrophic lateral sclerosis
|
|
926
|
| 5607 |
EGF
|
|
increases_phosphorylation of
|
AKT1
|
|
| 5616 |
EGF
|
|
increases_activity of
|
AKT1
|
|
|
11445557
|
Amyotrophic lateral sclerosis
|
CIDeRplus